Treprostinil

Treprostinil

SCHEMBL5090

CCCCC[C@@H](O)CC[C@H]1[C@@H]2Cc3cccc(OCC(=O)O)c3C[C@@H]2C[C@@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PTGIR

The experimentally established mechanism targets of Treprostinil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PTGIR known ✓ P43119 12/20 1.00
PTGER2 P43116 3/20 1.00
PTGER1 P34995 3/20 1.00
PTGDR Q13258 2/20 1.00
PTGFR P43088 6/20 0.45
TBXA2R P21731 2/20 0.45
PTGER3 P43115 1/20 0.37
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36
ADRA1A P35348 1/20 0.36
RECQL P46063 1/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Treprostinil SCHEMBL19910502 1.00 PTGIR (1.00) PTGIRPTGER2PTGER1PTGDRPTGFR
Treprostinil SCHEMBL9471418 1.00 PTGIR (1.00) PTGIRPTGER2PTGER1PTGDRPTGFR
Treprostinil SCHEMBL14524891 1.00 PTGIR (1.00) PTGIRPTGER2PTGER1PTGDRPTGFR
Treprostinil SCHEMBL14070147 1.00 PTGIR (1.00) PTGIRPTGER2PTGER1PTGDRPTGFR
Treprostinil SCHEMBL16321339 1.00 PTGIR (1.00) PTGIRPTGER2PTGER1PTGDRPTGFR
Treprostinil SCHEMBL11940504 1.00 PTGIR (1.00) PTGIRPTGER2PTGER1PTGDRPTGFR
Treprostinil SCHEMBL24243789 1.00 PTGIR (1.00) PTGIRPTGER2PTGER1PTGDRPTGFR
Treprostinil SCHEMBL18699351 1.00 PTGIR (1.00) PTGIRPTGER2PTGER1PTGDRPTGFR
Treprostinil SCHEMBL22282429 1.00 PTGIR (1.00) PTGIRPTGER2PTGER1PTGDRPTGFR
Treprostinil SCHEMBL21530472 1.00 PTGIR (1.00) PTGIRPTGER2PTGER1PTGDRPTGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 10034 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144751-A1 LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF PHARMOSA BIOPHARM INC. (TW) 2026-05-28 US claimed
EP-3810091-B1 COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION ABRAXIS BIOSCIENCE LLC (US) 2026-05-20 EP claimed
EP-4736841-A1 A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT IQ medical GmbH (DE) 2026-05-06 EP claimed
EP-4255391-B1 LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION METRIOPHARM AG (CH) 2026-05-06 EP claimed
US-12616803-B2 Apparatus for dispensing inhalant medicament METOPI PHARMACEUTICALS, INC. (US) 2026-05-05 US claimed
US-20260102366-A1 TREATMENT FOR INTERSTITIAL LUNG DISEASE UNITED THERAPEUTICS CORPORATION (US) 2026-04-16 US claimed
US-20260102473-A1 NOVEL FORMULATIONS ARECOR LTD (GB) 2026-04-16 US claimed
US-20260076872-A1 POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME SIO2 MEDICAL PRODUCTS LLC (US) 2026-03-19 US claimed
US-20260076929-A1 TREATMENT FOR INTERSTITIAL LUNG DISEASE UNITED THERAPEUTICS CORPORATION (US) 2026-03-19 US claimed
US-20260076928-A1 TREATMENT FOR INTERSTITIAL LUNG DISEASE UNITED THERAPEUTICS CORPORATION (US) 2026-03-19 US claimed
WO-2005058329-A1 USE OF TREPROSTINIL TO IMPROVE KIDNEY FUNCTIONS UNITED THERAPEUTICS CORPORATION (US) 2005-06-30 WO claimed
WO-2005058303-A1 USE OF TREPROSTINIL TO TREAT AND PREVENT ISCHEMIC LESIONS UNITED THERAPEUTICS CORPORATION (US) 2005-06-30 WO claimed
US-20050119330-A1 Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2005-06-02 US claimed
WO-2005046575-A2 AMINO ACID PRODRUGS SIGNATURE R & D HOLDINGS, LCC (US) 2005-05-26 WO claimed
US-20050085540-A1 Vasodilation; anticoagulants; thrombosis; antiproliferative agents ; angiogenesis inhibitors; drug delivery; bioavailability; oral administering UNITED THERAPEUTICS CORPORATION 2005-04-21 US claimed
US-20050080140-A1 Method for treating or preventing inflammatory disorders ANGES MG, INC. (JP) 2005-04-14 US claimed
WO-2005007081-A2 COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS UNITED THERAPEUTICS CORPORATION (US) 2005-01-27 WO claimed
WO-2004089416-A2 COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT NOVO NORDISK A/S (DK) 2004-10-21 WO claimed
US-20040105819-A1 comprise respiratory drug condensation aerosol particles; selected from the group consisting of beta -adrenergics, methylxanthines, anticholinergics, corticosteroids, mediator-release inhibitors, anti-leukotriene drugs, asthma inhibitors etc ALEXZA MOLECULAR DELIVERY CORPORATION (US) 2004-06-03 US claimed
WO-2004019952-A1 USE OF PROSTACYCLIN AND ANALOGS THEREOF FOR IMPROVING VENOUS FLOW UNIVERSITÀ 'CAMPUS BIO-MEDICO' DI ROMA (IT) 2004-03-11 WO claimed